{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:34:23Z","timestamp":1772134463594,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10067-018-4299-4","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T21:11:53Z","timestamp":1537564313000},"page":"523-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-7530","authenticated-orcid":false,"given":"Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zu-chun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,22]]},"reference":[{"issue":"0 2","key":"4299_CR1","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A (2013) Janus kinase Inhibitors in autoimmune diseases. Ann Rheum Dis 72(0 2):ii111\u2013ii115","journal-title":"Ann Rheum Dis"},{"key":"4299_CR2","unstructured":"Steve C (2017) Janus kinase inhibitors for autoimmune disorders. Therapy review"},{"key":"4299_CR3","doi-asserted-by":"publisher","unstructured":"Rivellese F, Lobasso A, Barbieri L, Liccardo B, De Paulis A, Rossi FW (2018) Novel therapeutic approaches in rheumatoid arthritis: role of Janus kinases inhibitors. Curr Med Chem 25. \n                    https:\/\/doi.org\/10.2174\/0929867325666180209145243","DOI":"10.2174\/0929867325666180209145243"},{"key":"4299_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbpa.2016.03.006","volume":"32","author":"K Yamaoka","year":"2016","unstructured":"Yamaoka K (2016) Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 32:29\u201333","journal-title":"Curr Opin Chem Biol"},{"key":"4299_CR5","first-page":"84","volume":"9","author":"A Louder","year":"2016","unstructured":"Louder A, Singh A, Saverno K et al (2016) Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 9:84\u201393","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"4299_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rdc.2016.09.008","volume":"43","author":"P Sivaraman","year":"2017","unstructured":"Sivaraman P, Cohen SB (2017) Malignancy and Janus kinase inhibition. Rheum Dis Clin N Am 43(1):79\u201393","journal-title":"Rheum Dis Clin N Am"},{"key":"4299_CR7","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"issue":"6","key":"4299_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS, ORAL Solo Investigators (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495\u2013507","journal-title":"N Engl J Med"},{"issue":"16","key":"4299_CR9","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"issue":"16","key":"4299_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cie\u015blak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537\u20131550","journal-title":"N Engl J Med"},{"issue":"5","key":"4299_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S (2016) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-termextension study. J Am Acad Dermatol 74(5):841\u2013850","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4299_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B, Standard Investigators ORAL (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508\u2013519","journal-title":"N Engl J Med"},{"issue":"9865","key":"4299_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C, ORAL Step investigators (2013) To facitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoidarthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3trial. Lancet 381(9865):451\u2013460","journal-title":"Lancet"},{"issue":"4","key":"4299_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patientswith active rheumatoid arthritis: a randomized trial. Ann Intern Med 159(4):253\u2013261","journal-title":"Ann Intern Med"},{"key":"4299_CR15","unstructured":"Higgins JP, et al. (2008) Assessing risk of bias in included studies, in Cochrane handbook for systematic reviews of interventions. Wiley 187\u2013241"},{"issue":"8","key":"4299_CR16","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D Heijde van der","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76(8):1340\u20131347","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4299_CR17","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-013-2329-9","volume":"32","author":"P Kawalec","year":"2013","unstructured":"Kawalec P, Mikrut A, Wi\u015bniewska N, Pilc A (2013) The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 32(10):1415\u20131424","journal-title":"Clin Rheumatol"},{"issue":"3","key":"4299_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumabmonotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying anti rheumatic drugs. Arthritis Rheum 64(3):617\u2013629","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4299_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/exd.12265","volume":"23","author":"K Ghoreschi","year":"2014","unstructured":"Ghoreschi K, Gadina M (2014) Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol 23(1):7\u201311","journal-title":"Exp Dermatol"},{"issue":"1","key":"4299_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.12266","volume":"169","author":"WC Ports","year":"2013","unstructured":"Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K (2013) A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169(1):137\u2013145","journal-title":"Br J Dermatol"},{"key":"4299_CR21","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377\u20132386","journal-title":"N Engl J Med"},{"key":"4299_CR22","doi-asserted-by":"publisher","first-page":"e000262","DOI":"10.1136\/rmdopen-2016-000262","volume":"2","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Huizinga T, Kavanaugh AF et al (2016) Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2:e000262","journal-title":"RMD Open"},{"issue":"18","key":"4299_CR23","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S (2017) Tofacitinib: a review in rheumatoid arthritis. Drugs 77(18):1987\u20132001","journal-title":"Drugs"},{"issue":"3","key":"4299_CR24","first-page":"430","volume":"34","author":"GV Wallenstein","year":"2016","unstructured":"Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, Genovese MC, Gomez Reino J, Gruben D, Kremer J, Krishnaswami S, Lee EB, Pascual-Ramos V, Strand V, Zwillich SH (2016) Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two phase 2 randomised controlled trials. Clin Exp Rheumatol 34(3):430\u2013442","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"4299_CR25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5312\/wjo.v5.i4.504","volume":"5","author":"LM Lundquist","year":"2014","unstructured":"Lundquist LM, Cole SW, Sikes ML (2014) Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 5(4):504\u2013511","journal-title":"World J Orthop"},{"issue":"7","key":"4299_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253\u20131262","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4299_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13075-018-1539-6","volume":"20","author":"MA\u00c1 Machado","year":"2018","unstructured":"Machado MA\u00c1, Moura CS, Guerra SF, Curtis JR, Abrahamowicz M, Bernatsky S (2018) Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther 20(1):60","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4299_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","volume":"56","author":"H Schulze-Koops","year":"2017","unstructured":"Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, Wang L (2017) Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford) 56(1):46\u201357","journal-title":"Rheumatology (Oxford)"},{"key":"4299_CR29","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60:1895\u20131905","journal-title":"Arthritis Rheum"},{"key":"4299_CR30","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Y Tanaka","year":"2011","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63:1150\u20131158","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4299_CR31","doi-asserted-by":"publisher","first-page":"357904","DOI":"10.1155\/2013\/357904","volume":"2013","author":"H Ni","year":"2013","unstructured":"Ni H, Moe S, Myint KT, Htet A (2013) Oral Janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib. ISRN Rheumatol 2013:357904","journal-title":"ISRN Rheumatol"},{"issue":"1","key":"4299_CR32","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1038\/jidsymp.2013.29","volume":"16","author":"M Gadina","year":"2013","unstructured":"Gadina M (2013) Janus kinases: an ideal target for the treatment of autoimmune diseases. J Investig Dermatol Symp Proc 16(1):S70\u2013S72","journal-title":"J Investig Dermatol Symp Proc"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4299-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T19:13:20Z","timestamp":1569093200000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4299-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4299"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4299-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,22]]},"assertion":[{"value":"5 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}